thumbnail image


  • Home
  • …  
    • Home


  • Home
  • …  
    • Home
  • Home
  • About us
    • Overview
    • Vision, Mission, and Values
    • Company presentation
    • Contact us
  • Patient
    • Overview
    • LVGN6051
    • LVGN7409
    • LVGN1673
    • LVGN3616
    • Resources
  • Science
    • Pipeline
    • xLinkAbTM platform
    • CD137/4-1BB
    • CD40
    • PD-1
    • Publications
  • Media
    • Press release
    • Company presentation
    • Lyvgen Journal
  • Partner
    • Careers
    • Research
    • Business
    • Clinical Trial
    • Contact us
  • Search
    •  

       

       

       

       

       

       

       

       

       

    • Lyvgen Biopharma Completes Series C Funding Led by IDG Capital

      February 23, 2021 - Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it has completed Series C founding. This round of financing was led by IDG Capital and included Shanghai FTZ Fund, Suzhou Longmen Venture Capital, CHENGWEI Capital and others, with China Renaissance Group as the exclusive financial adviser.

      February 23, 2021

       

      Lyvgen Announces First in Human Dosing of LVGN7409 CD40 Agonist Monoclonal Antibody in a Phase 1 Clinical Trial for the Treatment of Advanced or Metastatic Malignancy in the US

      January 26, 2021 - Lyvgen, a clinical-stage biotechnology company, today announced first-in-human (FIH) dosing of its xLinkAb product LVGN7409 (CD40 agonist), a bi-functional monoclonal antibody optimally activating CD40 upon FcγRIIB-mediated cross-linking.

      January 26, 2021

      Lyvgen Appoints Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development

      Suzhou, China, October 19, 2020 – Lyvgen Biopharma, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, is pleased to announce today the appointment of Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development. This appointment forms part of Lyngen’s strategic drive to strengthen CMC capabilities including GMP manufacturing.

      October 19, 2020

      Lyvgen Biopharma (Suzhou) officially opened in BioBAY, Suzhou, China.

      Lyvgen Biopharma (Suzhou) officially opened in BioBAY on June 10, 2020. Founded by Dr. Jieyi Wang in 2016, Lyvgen focuses on the development of novel immune-oncology (IO) agonist antibodies. At present, the company has built an CMC center of 2,000 square meters of therapeutic antibodies in BioBAY, Suzhou, China. The company headquarters, R&D center and GMP production site are also under active preparation. Follow us on Linkedlin.

      June 10, 2020

      Lyvgen Announces Clinical Trial Collaboration With MSD

      Phase 1 clinical trials evaluating LVGN6051 second generation 4-1BB (CD137) agonist antibody and KEYTRUDA® (pembrolizumab) for the treatment of multiple types of cancer.

      June 09, 2020

      Inquiries

      General --------------------- Business Development

      info@lyvgen.com11111 bd@lyvgen.com

       

      Employment 111111111Clinical

      careers@lyvgen.com 1 1clinical@lyvgen.com

       

      +86 021-50663350 phone

      +86 021-50663370 fax

       

      Contact us on LinkedIn

      Shanghai__------------------__

      Suite 601B, Building 8, 1043 Ha Lei Road ----_------

      Suzhou

      Suite 137, Building C36, 188 Dongping Street

      Copyright © 2020 LYVGEN BIOPHARMA. All RightsReserved.

       沪公网安备 31011502015346号|沪ICP备20018873号-2

      Home
      About us
      xLinkAb
      Pipeline
    礼进生物(Lyvgen)的网站
    Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
    https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More